NeoGenomics Inc (NEO) - Total Liabilities
Based on the latest financial reports, NeoGenomics Inc (NEO) has total liabilities worth $517.77 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
NeoGenomics Inc - Total Liabilities Trend (2000–2025)
This chart illustrates how NeoGenomics Inc's total liabilities have evolved over time, based on quarterly financial data. See NEO current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
NeoGenomics Inc Competitors by Total Liabilities
The table below lists competitors of NeoGenomics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Norconsult ASA
OL:NORCO
|
Norway | Nkr4.47 Billion |
|
SANDUR MANGANESE AND IRON ORES LTD
NSE:SANDUMA
|
India | Rs22.57 Billion |
|
No Va Land Investment Group Corp
VN:NVL
|
Vietnam | ₫193.31 Trillion |
|
Anhui Water Resources Development Co Ltd
SHG:600502
|
China | CN¥193.30 Billion |
|
Xiangyu Medical Co. Ltd. A
SHG:688626
|
China | CN¥1.23 Billion |
|
Avino Silver & Gold Mines Ltd
TO:ASM
|
Canada | CA$53.59 Million |
|
Chongqing Gas Grp Corp Ltd
SHG:600917
|
China | CN¥4.65 Billion |
Liability Composition Analysis (2000–2025)
This chart breaks down NeoGenomics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see NeoGenomics Inc stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NeoGenomics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NeoGenomics Inc (2000–2025)
The table below shows the annual total liabilities of NeoGenomics Inc from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $523.27 Million | -28.87% |
| 2024-12-31 | $735.70 Million | -0.54% |
| 2023-12-31 | $739.69 Million | -0.31% |
| 2022-12-31 | $742.01 Million | -2.56% |
| 2021-12-31 | $761.50 Million | +158.98% |
| 2020-12-31 | $294.04 Million | +45.49% |
| 2019-12-31 | $202.10 Million | +9.50% |
| 2018-12-31 | $184.57 Million | +33.94% |
| 2017-12-31 | $137.81 Million | -8.45% |
| 2016-12-31 | $150.52 Million | +15.93% |
| 2015-12-31 | $129.84 Million | +527.23% |
| 2014-12-31 | $20.70 Million | +13.71% |
| 2013-12-31 | $18.20 Million | -12.71% |
| 2012-12-31 | $20.86 Million | +48.41% |
| 2011-12-31 | $14.05 Million | +33.62% |
| 2010-12-31 | $10.52 Million | +44.02% |
| 2009-12-31 | $7.30 Million | +26.02% |
| 2008-12-31 | $5.79 Million | +38.00% |
| 2007-12-31 | $4.20 Million | +36.44% |
| 2006-12-31 | $3.08 Million | +48.31% |
| 2005-12-31 | $2.08 Million | +103.70% |
| 2004-12-31 | $1.02 Million | +16.44% |
| 2003-12-31 | $874.84K | +106.09% |
| 2002-12-31 | $424.49K | +127.96% |
| 2001-12-31 | $186.22K | +48.94% |
| 2000-12-31 | $125.03K | -- |
About NeoGenomics Inc
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to dise… Read more